Tumor escape mechanisms in prostate cancer

Area of Science:

• Oncology
• Immunology
• Cancer Research

Background:

• Immunotherapy trials in prostate cancer (PC) have successfully induced antigen-specific T cells.
• However, limited clinical success in tumor regression and survival has been observed despite T cell induction.

Purpose of the Study:

• To review the tumor escape strategies that contribute to the failure of immunotherapy vaccines in prostate cancer.
• To highlight the need for novel therapeutic approaches to overcome these escape mechanisms.

Main Methods:

• This is a review article, synthesizing existing evidence on tumor escape mechanisms in prostate cancer immunotherapy.
• The review discusses various biological and cellular factors implicated in vaccine failure.

Main Results:

• Prostate tumors employ multiple escape strategies, including impaired antigen presentation and immunosuppressive factors.
• Defects in T cell function, such as T cell receptor dysfunction and induced T cell death, are prevalent.
• The tumor microenvironment in PC often contains tolerogenic dendritic cells and regulatory T cells, promoting immune suppression.

Conclusions:

• Overcoming tumor escape mechanisms is crucial for improving immunotherapy efficacy in prostate cancer.
• Novel strategies combining immunotherapies with agents targeting immunosuppression, T cell function, and hormonal therapies are warranted.
• Further investigation into combined therapeutic approaches, including small molecule inhibitors, adoptive T cell transfer, regulatory T cell depletion, and enhanced vaccine strategies, is essential for advancing PC treatment.